Triple Negative Breast Cancer (TNBC) is the most aggressive type of breast cancer and is associated with high probability of metastasis and poor prognosis. Chemotherapeutics and surgery remain the most common options for TNBC patients; however chemotherapeutic resistance and relapse of tumors limit the progression free survival and patient life span. This review provides an overview of recent chemotherapeutics that are in clinical trial, and the combination of drugs that are being investigated to overcome the drug resistance and to improve patient survival in different molecular subtypes of TNBCs. Nanotherapeutics have emerged as a promising platform for TNBC treatment and aim to improve the selectivity and solubility of drugs, reduce systemic side effects, and overcome multi-drug resistance. The study explores the role of nanoparticles for TNBC treatment and summarizes the types of nanoparticles that are in clinical trials. Poly(L-lactide-co-glycolide) (PLGA) is the most studied polymeric carrier for drug delivery and for TNBC treatment in research and in clinics. This study specifically highlights the recent advancements in PLGA formulations and their applications for TNBC treatment. Significance Statement This mini review summarizes the progress on chemotherapeutics and nanoparticles delivery for treatment of TNBC and specifically highlights the lead compounds that are in clinical trials.
Keywords: Nanoparticles; animal/nonclinical/preclinical.
Copyright © 2024 American Society for Pharmacology and Experimental Therapeutics.